Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: Neratinib Diarrhea Prophylaxis in HER2+ Breast Cancer
NCT02400476Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Feb 2015
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of neratinib in HER2-positive breast cancer, sponsored by Puma Biotechnology, Inc.. Started Feb 2015; status: completed.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02400476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400476.